Young and the Invested on MSN
Grab your magnifying glass: These are some of the worst shrinkflation offenders
This article looks at the biggest offenders in the shrinkflation game.
Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its organization. The California pharma has stitched together a deal worth up to $840 ...
Divi’s Laboratories shares gained over 3 per cent as analysts flagged 2026 as a potential inflection point, driven by a strong line-up of growth catalysts across GLP-1 drugs, contrast media, custom ...
Ram is keeping its long-haul bet on durability alive for another year, extending its expanded powertrain coverage so new truck buyers can lock in protection well into the next decade. The move keeps ...
Medicare selected Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028. Rep. Rich McCormick, R-Ga., discusses President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results